论文部分内容阅读
目的:探讨中药制剂血美安胶囊治疗乙型肝炎病毒相关血小板减少症的临床疗效。方法:选取收治的乙型肝炎病毒相关血小板减少症患者112例,随机分为两组;观察组60例口服中药制剂血美安胶囊,对照组52例静脉注射丙种球蛋白;根据两组患者的骨髓巨核细胞计数,外周血血小板计数,T淋巴细胞亚群计数,补体C3、C4含量,以及细胞因子IL-6、TNF-α水平对比分析其疗效。结果:观察组患者的临床有效率显著高于对照组(P<0.05);两组患者的外周血血小板、产板骨髓巨核细胞及CD4+、CD4+/CD8+细胞计数均有所升高,骨髓巨核细胞总计数有所降低,观察组各项指标变化幅度显著高于对照组(P<0.05,P<0.01);两组患者的血清补体C3、C4含量有所升高,IL-6、TNF-α含量有所降低,观察组各项指标变化幅度显著高于对照组(P<0.05,P<0.01)。结论:中药血美安胶囊治疗乙型肝炎病毒相关血小板减少症能够发挥多靶点优势,且不良反应小,可长期服用,疗效显著。
Objective: To investigate the clinical efficacy of Chinese medicine preparation Xuemeian Capsule in the treatment of hepatitis B virus associated thrombocytopenia. Methods: One hundred and twelve patients with hepatitis B virus thrombocytopenia were selected and randomly divided into two groups. 60 cases in the observation group were treated with Xuemeian Capsule, 52 cases in the control group were given intravenous gamma globulin. According to the two groups Bone marrow megakaryocyte count, peripheral blood platelet count, count of T lymphocyte subsets, complement C3, C4 content, and the levels of cytokines IL-6, TNF-αwere analyzed. Results: The clinical effective rate in the observation group was significantly higher than that in the control group (P <0.05). The counts of peripheral blood platelet, platelet marrow megakaryocyte and CD4 +, CD4 + / CD8 + cells in both groups were increased, The total count decreased, the changes in the indicators of the observation group was significantly higher than the control group (P <0.05, P <0.01); serum complement C3, C4 levels were increased, IL-6, TNF- Content decreased, the changes in the indicators of the observation group was significantly higher than the control group (P <0.05, P <0.01). Conclusion: The Chinese medicine Xuemeian Capsule can treat hepatitis B virus-related thrombocytopenia with multi-target advantages and low adverse reaction, which can be used for a long time and has obvious curative effect.